In addition, since the change in the ALBI score may be prognostic in patients receiving atezolizumab and bevacizumab, it should be studied the clinical value of the ALBI grade in patients that receive tyrosine kinase (TK) inhibitors after novel first-line combinations for HCC including immunotherapies. This evidence concerns the gene TKT and hepatocellular carcinoma.